BIM 44002

Drug Profile

BIM 44002

Latest Information Update: 14 Dec 2001

Price : $50

At a glance

  • Originator Ipsen
  • Class Antihypercalcaemics; Peptides
  • Mechanism of Action Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypercalcaemia

Most Recent Events

  • 14 Dec 2001 Discontinued-Clinical for Hypercalcaemia in Spain (Unknown route)
  • 14 Dec 2001 Discontinued-Clinical for Hypercalcaemia in France (Unknown route)
  • 12 Sep 2000 No-Development-Reported for Hypercalcaemia in Spain (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top